
Roger L Shapiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4709250/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. New England Journal of Medicine, 2018, 379, 979-981.	27.0	281
2	Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. New England Journal of Medicine, 2019, 381, 827-840.	27.0	269
3	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
4	Selection bias at the heterosexual HIV-1 transmission bottleneck. Science, 2014, 345, 1254031.	12.6	225
5	Infant Morbidity, Mortality, and Breast Milk Immunologic Profiles among Breastâ€Feeding HIVâ€Infected and HIVâ€Uninfected Women in Botswana. Journal of Infectious Diseases, 2007, 196, 562-569.	4.0	137
6	Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. The Lancet Global Health, 2018, 6, e804-e810.	6.3	117
7	Highly Active Antiretroviral Therapy Started during Pregnancy or Postpartum Suppresses HIVâ€∎ RNA, but Not DNA, in Breast Milk. Journal of Infectious Diseases, 2005, 192, 713-719.	4.0	112
8	Antiretroviral Concentrations in Breastâ€Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment. Journal of Infectious Diseases, 2005, 192, 720-727.	4.0	110
9	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	30.7	87
10	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5393-400.	7.1	85
11	Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Aids, 2006, 20, 1281-1288.	2.2	82
12	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet, The, 2021, 397, 1276-1292.	13.7	82
13	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Science Translational Medicine, 2019, 11, .	12.4	74
14	Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS ONE, 2015, 10, e0134037.	2.5	49
15	Mortality among HIVâ€Exposed Infants: The First and Final Frontier. Clinical Infectious Diseases, 2010, 50, 445-447.	5.8	47
16	Modest reduction in adverse birth outcomes following the COVID-19 lockdown. American Journal of Obstetrics and Gynecology, 2021, 224, 615.e1-615.e12.	1.3	47
17	Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu) Tj ETQq1 1 e491-e500.	0.78431 6.3	4 rgBT /Ove 39
18	Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes. Aids, 2018, 32, 113-120.	2.2	35

ROGER L SHAPIRO

#	Article	IF	CITATIONS
19	An Augmented SMS Intervention to Improve Access to Antenatal CD4 Testing and ART Initiation in HIV-Infected Pregnant Women: A Cluster Randomized Trial. PLoS ONE, 2015, 10, e0117181.	2.5	34
20	Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies. Clinical Infectious Diseases, 2018, 66, 1668-1677.	5.8	28
21	High Prevalence of Hypertension and Placental Insufficiency, but No In Utero HIV Transmission, among Women on HAART with Stillbirths in Botswana. PLoS ONE, 2012, 7, e31580.	2.5	27
22	Protease Inhibitors and Adverse Birth Outcomes: Is Progesterone the Missing Piece to the Puzzle?. Journal of Infectious Diseases, 2015, 211, 4-7.	4.0	22
23	Risk Factors for Early and Late Transmission of HIV via Breastâ€Feeding among Infants Born to HIVâ€Infected Women in a Randomized Clinical Trial in Botswana. Journal of Infectious Diseases, 2009, 199, 414-418.	4.0	21
24	Weight gain during pregnancy among women initiating dolutegravir in Botswana. EClinicalMedicine, 2020, 29-30, 100615.	7.1	21
25	In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana. Aids, 2018, 32, 1173-1183.	2.2	20
26	Hypertensive disease in pregnancy in Botswana: Prevalence and impact on perinatal outcomes. Pregnancy Hypertension, 2016, 6, 418-422.	1.4	19
27	The aetiology of diarrhoea, pneumonia and respiratory colonization of HIV-exposed infants randomized to breast- or formula-feeding. Paediatrics and International Child Health, 2016, 36, 189-197.	1.0	16
28	HIVâ€associated morbidity and mortality in a setting of high ART coverage: prospective surveillance results from a district hospital in Botswana. Journal of the International AIDS Society, 2019, 22, e25428.	3.0	16
29	Ending the evidence gap for pregnancy, HIV and coâ€infections: ethics guidance from the PHASES project. Journal of the International AIDS Society, 2021, 24, e25846.	3.0	16
30	Iron, folic acid, and multiple micronutrient supplementation strategies during pregnancy and adverse birth outcomes in Botswana. The Lancet Global Health, 2022, 10, e850-e861.	6.3	13
31	Therapeutic Levels of Lopinavir in Late Pregnancy and Abacavir Passage into Breast Milk in the Mma Bana Study, Botswana. Antiviral Therapy, 2013, 18, 1-6.	1.0	12
32	The effect of neonatal vitamin A supplementation on morbidity and mortality at 12 months: a randomized trial. International Journal of Epidemiology, 2016, 45, 2112-2121.	1.9	11
33	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003.	5.8	11
34	High Proportion of Deaths Attributable to HIV Among Postpartum Women in Botswana Despite Widespread Uptake of Antiretroviral Therapy. AIDS Patient Care and STDs, 2017, 31, 14-19.	2.5	10
35	Optimal breastfeeding durations for HIVâ€exposed infants: the impact of maternal <scp>ART</scp> use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	3.0	10
36	Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e148-e151.	1.3	10

ROGER L SHAPIRO

#	Article	IF	CITATIONS
37	HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. Journal of Infectious Diseases, 2016, 213, 1248-1252.	4.0	9
38	Methodological Challenges When Studying Distance to Care as an Exposure in Health Research. American Journal of Epidemiology, 2019, 188, 1674-1681.	3.4	9
39	Drawing lines in the sand: the boundaries of the HIV pandemic in perspective. Social Science and Medicine, 2002, 55, 2189-2191.	3.8	8
40	HIV-related mortality at a district hospital in Botswana. International Journal of STD and AIDS, 2017, 28, 277-283.	1.1	8
41	HIV Exposure and Formula Feeding Predict Under-2 Mortality in HIV-Uninfected Children, Botswana. Journal of Pediatrics, 2018, 203, 68-75.e2.	1.8	8
42	Adverse Birth Outcomes in Botswana Among Women With Vertically or Horizontally Acquired Human Immunodeficiency Virus. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 252-258.	1.3	6
43	Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. Aids, 2021, 35, 2413-2421.	2.2	6
44	Limited surface examination to evaluate potential teratogens in a resourceâ€limited setting. Birth Defects Research, 2021, 113, 702-707.	1.5	5
45	Crossâ€sectional trends in HIV prevalence among pregnant women in Botswana: an opportunity for PrEP?. Journal of the International AIDS Society, 2022, 25, e25892.	3.0	5
46	Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana. PLoS ONE, 2020, 15, e0229500.	2.5	4
47	Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy. Southern African Journal of HIV Medicine, 2020, 21, 1023.	0.9	4
48	Are morbidity and mortality estimates from randomized controlled trials externally valid? A comparison of outcomes among infants enrolled into an RCT or a cohort study in Botswana. BMC Medical Research Methodology, 2021, 21, 212.	3.1	2
49	Prolonged Cotrimoxazole Prophylaxis Has No Impact on Child Growth in the First Two Years of Life: Findings from a Randomized Controlled Trial in Botswana. Journal of Pediatrics, 2022, 246, 266-270.e2.	1.8	2
50	Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana. AIDS Research and Human Retroviruses, 2021, 37, 16-23.	1.1	1
51	Antiâ€hypertensive use for nonâ€severe gestational hypertension in Botswana: A caseâ€control study. International Journal of Gynecology and Obstetrics, 2021, , .	2.3	1
52	Audit of Early Mortality among Patients Admitted to the General Medical Ward at a District Hospital in Botswana. Annals of Global Health, 2019, 85, .	2.0	1
53	2572. Decreased T-Cell Response, but Appropriate Antibody Production to Tetanus Vaccine Among HIV-Exposed Uninfected Infants in Botswana. Open Forum Infectious Diseases, 2018, 5, S75-S75.	0.9	0
54	2529. Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations with 24-Month Growth and Neurodevelopment. Open Forum Infectious Diseases, 2019, 6, S879-S879.	0.9	0

ROGER L SHAPIRO

#	Article	IF	CITATIONS
55	The aetiology of diarrhoea, pneumonia and respiratory colonization of HIV-exposed infants randomized to breast- or formula-feeding. Paediatrics and International Child Health, 0, , 1-9.	1.0	0
56	769. Mortality Among Inpatients After the Initiation of †Treat All' With Dolutegravir in Botswana. Open Forum Infectious Diseases, 2020, 7, S429-S429.	0.9	0
57	Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana. , 2020, 15, e0229500.		Ο
58	Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana. , 2020, 15, e0229500.		0
59	Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana. , 2020, 15, e0229500.		0
60	Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana. , 2020, 15, e0229500.		0
61	Title is missing!. , 2020, 15, e0237252.		0
62	Title is missing!. , 2020, 15, e0237252.		0
63	Title is missing!. , 2020, 15, e0237252.		0
64	Title is missing!. , 2020, 15, e0237252.		0
65	Title is missing!. , 2020, 15, e0237252.		0
66	Title is missing!. , 2020, 15, e0237252.		0